Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
23.22
-0.46 (-1.94%)
May 29, 2026, 4:00 PM EDT - Market closed
Pacira BioSciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 734.86 | 726.41 | 700.97 | 674.98 | 666.82 | 541.53 | |
Revenue Growth (YoY) | 4.57% | 3.63% | 3.85% | 1.22% | 23.14% | 26.04% |
Cost of Revenue | 151.86 | 149.75 | 170.43 | 184.67 | 199.3 | 140.26 |
Gross Profit | 583.01 | 576.66 | 530.54 | 490.31 | 467.53 | 401.28 |
Selling, General & Admin | 375.93 | 368.76 | 294.1 | 269.44 | 254.52 | 199.35 |
Depreciation & Amortization Expenses | 57.29 | 57.29 | 57.29 | 57.29 | 57.29 | 13.55 |
Research & Development | 119.69 | 117.31 | 81.58 | 76.26 | 84.8 | 55.55 |
Other Operating Expenses | 6 | 14.11 | 170.95 | -0.35 | 10.9 | 42.91 |
Total Operating Expenses | 558.91 | 557.47 | 603.91 | 402.63 | 407.5 | 311.35 |
Operating Income | 24.1 | 19.19 | -73.37 | 87.68 | 60.02 | 89.92 |
Interest Income | 17.77 | 22.73 | 19.69 | 11.44 | 4.54 | 0.9 |
Interest Expense | -16.57 | -17.45 | -16.57 | -20.31 | -39.98 | -31.75 |
Other Non-Operating Income (Expense) | -12.14 | -7.6 | 7.15 | -17.11 | -11.29 | -2.67 |
Total Non-Operating Income (Expense) | -10.94 | -2.32 | 10.27 | -25.97 | -46.72 | -33.52 |
Pretax Income | 13.17 | 16.87 | -63.11 | 61.7 | 13.3 | 56.4 |
Provision for Income Taxes | 8.03 | 9.84 | 36.45 | 19.75 | -2.61 | 14.42 |
Net Income | 5.14 | 7.03 | -99.56 | 41.96 | 15.91 | 41.98 |
Net Income to Common | 5.14 | 7.03 | -99.56 | 41.96 | 15.91 | 41.98 |
Net Income Growth | - | - | - | 163.72% | -62.10% | -71.15% |
Shares Outstanding (Basic) | 43 | 45 | 46 | 46 | 46 | 44 |
Shares Outstanding (Diluted) | 43 | 45 | 46 | 52 | 47 | 46 |
Shares Change (YoY) | -9.59% | -2.60% | -11.03% | 11.69% | 1.99% | 4.46% |
EPS (Basic) | 0.12 | 0.16 | -2.15 | 0.91 | 0.35 | 0.95 |
EPS (Diluted) | 0.12 | 0.16 | -2.15 | 0.89 | 0.34 | 0.92 |
EPS Growth | - | - | - | 161.77% | -63.04% | -72.37% |
Shares Outstanding | 39.31 | 41.12 | 46.24 | 46.48 | 45.93 | 44.73 |
Free Cash Flow | - | 0 | 178.75 | 139.49 | 115.2 | 79.85 |
Free Cash Flow Growth | - | - | 28.15% | 21.09% | 44.27% | 103.54% |
Free Cash Flow Per Share | - | - | 3.87 | 2.68 | 2.48 | 1.75 |
Gross Margin | 79.34% | 79.39% | 75.69% | 72.64% | 70.11% | 74.10% |
Operating Margin | 3.28% | 2.64% | -10.47% | 12.99% | 9.00% | 16.61% |
Profit Margin | 0.70% | 0.97% | -14.20% | 6.22% | 2.39% | 7.75% |
FCF Margin | - | 0.00% | 25.50% | 20.67% | 17.28% | 14.75% |
EBITDA | 24.1 | 19.19 | 5.41 | 163.25 | 151.53 | 118.47 |
EBITDA Margin | 3.28% | 2.64% | 0.77% | 24.19% | 22.72% | 21.88% |
EBIT | 24.1 | 19.19 | -73.37 | 87.68 | 60.02 | 89.92 |
EBIT Margin | 3.28% | 2.64% | -10.47% | 12.99% | 9.00% | 16.61% |
Effective Tax Rate | 60.98% | 58.31% | -57.77% | 32.00% | -19.60% | 25.57% |